瑞康医药(002589) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥2,025,130,031.90, a decrease of 39.47% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥11,447,150.75, representing a decline of 646.64% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥8,242,407.50, an increase of 105.57% compared to the previous year[5]. - Total operating revenue for Q3 2023 was CNY 6,105,062,530.67, a decrease of 44.1% compared to CNY 10,896,716,818.79 in the same period last year[20]. - Net profit for Q3 2023 was CNY 27,832,019.60, a decline of 80.9% from CNY 145,362,681.81 in Q3 2022[21]. - The total comprehensive income for Q3 2023 was CNY 27,832,019.60, significantly lower than CNY 145,362,681.81 in the same quarter last year[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥17,427,544,905.61, down 4.93% from the end of the previous year[5]. - The company's total assets decreased to CNY 17,427,544,905.61 from CNY 18,331,074,646.82, a reduction of 4.9%[19]. - Total liabilities amounted to CNY 11,731,512,783.32, down from CNY 12,579,267,518.31, indicating a decrease of 6.8%[19]. - The equity attributable to shareholders of the parent company increased to CNY 5,483,430,853.83 from CNY 5,407,787,638.68, reflecting a growth of 1.4%[19]. Cash Flow - Operating cash flow net amount was ¥332,495,045.47, an increase of 2.13% year-to-date[5]. - Cash inflow from operating activities totaled 7,277,559,775.64 CNY, down from 13,674,133,744.92 CNY year-on-year[22]. - Net cash flow from operating activities was 332,495,045.47 CNY, slightly up from 325,546,433.95 CNY in the previous period[22]. - Cash inflow from investment activities was 1,041,094,767.33 CNY, compared to 1,975,130,880.55 CNY in the previous period[23]. - Net cash flow from investment activities increased to 439,775,610.96 CNY from 155,565,052.30 CNY year-on-year[23]. - Cash inflow from financing activities was 15,528,940,865.23 CNY, down from 17,644,956,563.09 CNY in the previous period[23]. - Net cash flow from financing activities showed a negative balance of -827,867,599.15 CNY, worsening from -335,170,334.57 CNY in the previous period[23]. - The ending balance of cash and cash equivalents was 431,546,196.65 CNY, down from 982,174,121.42 CNY in the previous period[23]. Expenses - The company reported a 43.97% decrease in operating income for the year-to-date period, totaling ¥610,506.25[11]. - The company experienced a 52.90% reduction in selling expenses, amounting to ¥37,553.35, due to decreased sales activities[11]. - Research and development expenses for Q3 2023 were CNY 10,177,007.27, slightly down from CNY 10,359,536.42 in the previous year[20]. - Cash paid for purchasing goods and services decreased by 41.58% to ¥625.79 million, reflecting reduced sales revenue[13]. - Cash paid to employees decreased by 52.65% to ¥21.49 million, attributed to a reduction in the scope of consolidation[13]. - Cash paid for taxes decreased by 70.68% to ¥11.73 million compared to the previous year[13]. Investments - Investment income increased by 59.49% to ¥41,651.21, attributed to gains from the divestiture of subsidiaries[12]. - The company reported an investment income of CNY 416,512,053.59, an increase from CNY 261,149,688.26 year-over-year[20]. - Cash received from investment income fell by 81.17% to ¥0.08 million due to lower returns from financial products[13]. - Long-term equity investments increased by 63.73% to ¥714.13 million compared to the beginning of the year[17]. Shareholder Information - The number of common shareholders at the end of the reporting period was 89,860[15]. - The company's basic earnings per share were -¥0.0076, a decrease of 642.86% year-on-year[5]. - Basic earnings per share decreased to 0.0128 from 0.0406 in the previous period[22]. Audit and Reporting - The company did not undergo an audit for the third quarter report[24]. - The report was issued by the board of directors on October 31, 2023[25].